(RTTNews) - Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics's Enhanze ...

Roche announced that the United States Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

The biggest stories of the day delivered to your inbox.

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

Apple recently announced the Apple iPhone 16, nine months after Samsung unveiled the Galaxy S24 series. While being similar in a lot of ways, not the least of which is their status as the cheapest ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could ...

The Jets added plenty of fuel to the AFC East discussion on Thursday night. New York thoroughly dominated its division rival seemingly hitting their stride in a 24-3 win over the Patriots. Aaron ...